Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The goals of treatment of type 2 diabetes are to reduce the risk of diabetic complications and, as a result, improve the quality and, possibly, duration of life. For several decades, authoritative guidelines instructed clinicians to strictly control glucose levels of patients with diabetes to accomplish these goals. In addition, in the 1990s, the US Food and Drug Administration (FDA) began to approve drugs for the treatment of diabetes based on hemoglobin A1c (HbA1c) levels as the outcome. The prevailing concept was that risk reduction could be achieved by a clinical focus on reaching target values of HbA1c, agnostic to the strategies used. This concept, analogous to early notions about lipid lowering, persisted despite the failure of trials evaluating tight glycemic targets, as assessed by HbA1c levels, to reduce the risk of heart disease or improve survival.1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Rodríguez-Gutiérrez, R., & Montori, V. M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002901 · Cited by 176
Cited by
Ikramuddin, S., Korner, J., Lee, W.-J., Thomas, A. J., Connett, J. E., Bantle, J. P., Leslie, D. B., Wang, Q., Inabnet, W. B., Jeffery, R. W., et al. (2018) · JAMA · doi:10.1001/jama.2017.20813 · Cited by 291
“Native American 1 (2) 2 (4) Other 2 (4) 0 (0)”
Stamatakis, E., Ekelund, U., Ding, D., Hamer, M., Bauman, A. E., & Lee, I.-M. (2019) · British Journal of Sports Medicine · doi:10.1136/bjsports-2018-099131 · Cited by 284
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Richter, B., Hemmingsen, B., Metzendorf, M.-I., & Takwoingi, Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012661.pub2 · Cited by 283
An Effective Model of Diabetes Care and Education: Revising the AADE7 Self-Care Behaviors ®
American Association of Diabetes Educators (2020) · The Diabetes Educator · doi:10.1177/0145721719894903 · Cited by 184
Kebede, M. M., Liedtke, T. P., Möllers, T., & Pischke, C. R. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.7135 · Cited by 69
“Lipska and Krumholz [83] challenged this glucocentric approach, reporting that the effectiveness indicator of interventions in T2DM is moving away from the historic surrogate marker (ie, HbA1c) to cardiovascular outcomes.”
Background
Metadata
- Authors
- Lipska, K. J., & Krumholz, H. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-03-14
- Volume
- 317
- Issue
- 10
- Pages
- 1017
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2582793111
- Cited by
- 85
- References
- 7
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is Hemoglobin A1c the Right Outcome for Studies of Diabetes? https://app.cochat.ai/papers/10.1001/jama.2017.0029
- The paper
- Lipska, K. J., & Krumholz, H. M. (2017). Is Hemoglobin A1c the Right Outcome for Studies of Diabetes? JAMA. https://doi.org/10.1001/jama.2017.0029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.